Lun - Ven 8:00 - 17:00
cenobamatecenobamate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate. cenobamate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. chlorthalidonetadalafil increases effects of chlorthalidone by pharmacodynamic synergism.
Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling. tucatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acebutololtadalafil increases effects of acebutolol by pharmacodynamic synergism. tadalafil increases effects of acebutolol by pharmacodynamic synergism.
acetazolamidetadalafil increases effects of acetazolamide by pharmacodynamic synergism. tadalafil increases effects of acetazolamide by pharmacodynamic synergism. alfuzosintadalafil increases effects of alfuzosin by pharmacodynamic synergism. tadalafil increases effects of alfuzosin by pharmacodynamic synergism. aliskirentadalafil increases effects of aliskiren by pharmacodynamic synergism. tadalafil increases effects of chlorthalidone by pharmacodynamic synergism.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 2.5mg | 90 + 6 Pills | 112.43€ 107.08€ | |
| Cialis Generic | 5mg | 30 + 4 Pills | 53.56€ 51.01€ | |
| Cialis Soft Tabs | 20mg | 90 + 6 Pills | 216.71€ 206.39€ | |
| Cialis Professional | 20mg | 30 Pills | 104.57€ 99.59€ | |
| Cialis Original | 20mg | 34 + 2 Pills | 183.99€ 175.23€ | |
| Cialis Original | 20mg | 14 + 2 Pills | 95.75€ 91.19€ | |
| Cialis Professional | 20mg | 180 + 4 Pills | 423.11€ 402.96€ | |
| Cialis Professional | 40mg | 90 + 2 Pills | 348.59€ 331.99€ | |
| Cialis Generic | 60mg | 360 + 10 Pills | 570.52€ 543.35€ | |
| Cialis Generic | 2.5mg | 270 + 10 Pills | 199.64€ 190.13€ | |
| Cialis Super Active | 20mg | 120 + 16 Pills | 382.15€ 363.95€ | |
| Cialis Professional | 40mg | 120 + 4 Pills | 436.68€ 415.89€ | |
| Cialis Generic | 2.5mg | 30 + 4 Pills | 51.95€ 49.48€ | |
| Cialis Soft Tabs | 20mg | 30 + 4 Pills | 87.43€ 83.27€ |
cimetidinecimetidine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cimetidine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Benefit | Description | Evidence Level |
|---|---|---|
| Improved Erectile Function | Consistent daily use can help maintain erectile stability | Moderate |
| Increased Spontaneity | Reduced planning for medication enhances spontaneity | Moderate |
| Better Confidence | Steady performance may boost confidence | Anecdotal |
| Long-term Health Benefits | Possible cardiovascular benefits with regular use | Limited |
clevidipinetadalafil increases effects of clevidipine by pharmacodynamic synergism. tadalafil increases effects of clevidipine by pharmacodynamic synergism.
tadalafil increases effects of bisoprolol by pharmacodynamic synergism. bosentanbosentan will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bosentan will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonidebudesonide will decrease the level or effect of tadalafil cialis without prescription in canada by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
bumetanidetadalafil increases effects of bumetanide by pharmacodynamic synergism. tadalafil increases effects of bumetanide by pharmacodynamic synergism. bumetanide intranasaltadalafil increases effects of bumetanide intranasal by pharmacodynamic synergism. tadalafil increases effects of bumetanide intranasal by pharmacodynamic synergism. butalbitalbutalbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clonidinetadalafil increases effects of clonidine by pharmacodynamic synergism. tadalafil increases effects of clonidine by pharmacodynamic synergism.
butalbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. candesartantadalafil increases effects of candesartan by pharmacodynamic synergism. tadalafil increases effects of candesartan by pharmacodynamic synergism. captopriltadalafil increases effects of captopril by pharmacodynamic synergism. tadalafil increases effects of captopril by pharmacodynamic synergism.
carbamazepinecarbamazepine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For patients with ED, monitor response to tadalafil carefully because of potential for decreased effectiveness. carbamazepine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. carvediloltadalafil increases effects of carvedilol by pharmacodynamic synergism. tadalafil increases effects of carvedilol by pharmacodynamic synergism. clotrimazoleclotrimazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clotrimazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. conivaptanconivaptan will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
tadalafil increases effects of aliskiren by pharmacodynamic synergism. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy. amiloridetadalafil increases effects of amiloride by pharmacodynamic synergism. tadalafil increases effects of amiloride by pharmacodynamic synergism. amiodaroneamiodarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; increased levels may result in increased associated adverse events. amiodarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amlodipinetadalafil increases effects of amlodipine by pharmacodynamic synergism. tadalafil increases effects of amlodipine by pharmacodynamic synergism. aprepitantaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. conivaptan will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crizotinibcrizotinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. crizotinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crofelemercrofelemer increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. crofelemer increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Side Effect | Severity | Commonality | Recommendations |
|---|---|---|---|
| Headache | Mild | Very common | OTC pain relief, hydration |
| Flushing | Mild | Common | Cooling measures, reassurance |
| Nasal congestion | Mild | Common | Decongestants if needed |
| Muscle aches | Mild | Less common | Rest, hydration |
| Vision changes | Rare | Rare | Seek medical advice if occurs |
cyclosporinecyclosporine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
aprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. armodafinilarmodafinil will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. armodafinil will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
asenapinetadalafil increases effects of asenapine by pharmacodynamic synergism. tadalafil increases effects of asenapine by pharmacodynamic synergism. atazanaviratazanavir increases levels of tadalafil by decreasing metabolism. atazanavir increases levels of tadalafil by decreasing metabolism. atenololtadalafil increases effects of atenolol by pharmacodynamic synergism. dabrafenibdabrafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
tadalafil increases effects of atenolol by pharmacodynamic synergism. azilsartantadalafil increases effects of azilsartan by pharmacodynamic synergism. tadalafil increases effects of azilsartan by pharmacodynamic synergism. benazepriltadalafil increases effects of benazepril by pharmacodynamic synergism. tadalafil increases effects of benazepril by pharmacodynamic synergism.
betaxololtadalafil increases effects of betaxolol by pharmacodynamic synergism. tadalafil increases effects of betaxolol by pharmacodynamic synergism. bicalutamidebicalutamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bicalutamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bisoprololtadalafil increases effects of bisoprolol by pharmacodynamic synergism. dabrafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dasatinibdasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
dasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Avoid coadministration if tadalafil used for pulmonary arterial hpertension. Reduce tadalafil dose if used for erectile dysfunction. nirmatrelvir/ritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
tovorafenibtovorafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of tovorafenib (a weak CYP3A4 inducer) with CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures. If unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the CYP3A4 substrate prescribing information. tovorafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tucatinibtucatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasiroxdeferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités